After an early report that patients treated with angiotensin-converting enzyme (ACE) inhibitors had a lower than expected incidence of cancers, there was a large number of publications investigating the possible pathophysiological mechanism mediating this effect, as well as population studies comparing the incidence of cancers in patients treated with agents inhibiting the reninangiotensin system with their incidence in the general population. Several mechanisms are proposed to explain a potential anti-tumour activity of such agents in vitro in experimental animal models. However, the population studies are mostly inconclusive, although they do suggest a possible interaction between ACE genotypes and susceptibility to altered behaviour of certain tumours.
Introduction
The possibility that angiotensin-converting enzyme inhibitors (ACEis) may have a protective effect against cancer was first suggested in a provocative article by Lever et al., 1 who reported a lower-thanexpected incidence of breast and lung cancer in hypertensive patients undergoing long-term treatment with ACEis. This observation, based on a retrospective analysis of the records of 5207 patients attending the Glasgow Blood Pressure Clinic between 1 January 1980 and 31 December 1995, was rightly considered by the authors as a hypothesisgenerating finding. Indeed, interpretation of a statistical association between use of ACEis and cancer should take into account a number of important confounders, such as use of tobacco, lipid-lowering drugs of that era and hormone replacement therapy, all of which are more prevalent in hypertensive patients. Furthermore, acceptance of a causal relationship requires identification of plausible pathophysiological mechanisms that can be tested in animal models, as well as confirmation by controlled prospective clinical studies.
The purpose of this article is to review (a) the existing knowledge about a possible link between the known actions of ACEis and factors influencing the development of malignancies, and (b) the literature reporting statistical associations (or lack thereof) between ACEi treatment and incidence of specific cancers. To this aim, we conducted a literature search in PubMed using the key words angiotensin, ACE, malignancies/cancers. The search went as far back as the year 2000, with addition of specific inquiries about certain selected earlier articles mentioned in the bibliography of those yielded by the search.
The renin-angiotensin system (RAS) and carcinogenesis
Recent studies have shown local expression of several components of the RAS in cancer cells of various tissues, such as brain, lung, stomach, pancreas, breast, prostate, kidney, skin and cervix carcinomas. 2 There is increasing evidence that Angiotensin II (Ang II), which is generated by chymase or ACE, in addition to its effects on blood pressure, may play a role in various pathological situations involving regulation of cell proliferation, inflammation, angiogenesis, and tissue repair and development. The role of Ang II in cell proliferation and migration, as well as in several experimental models of angiogenesis, suggests that this peptide might be involved in certain important steps of carcinogenesis. [2] [3] [4] [5] It has been reported that ACEis, and Ang II type 1 (AT 1 ) receptor blockers (ARBs) have strong cytostatic properties in in vitro cultures of many normal and neoplastic cells. 6 Furthermore, there is evidence that the ACE has the effect of modifying gene expression, an effect unrelated to its enzymatic activity. 7 ACEi was also shown to be capable of inhibiting proliferation and invasion of cancer cells and reducing endothelial cell migration and angiogenesis in vitro, whereas tumour growth and metastasis were inhibited in vivo. 8 There is also evidence that the ACE genotype, that is, the insertion/deletion (I/D) polymorphisms, may play a role in the susceptibility for development of certain malignancies, as well as the propensity of certain tumours to metastasize. 9 Indeed, the DD polymorphism is associated with higher levels of circulating ACE-although this is not the ratelimiting step in the generation of Ang II, which is supposed to exert the tumourigenic effects. The proposed mechanisms mediating the anti-tumour activity of ACEis or ARBs include inhibition of matrix metalloproteases (MMPs)-a class of enzymes involved in extracellular matrix degradation-and reduced expression of vascular endothelial growth factor (VEGF), which would also inhibit tumour growth and development. Inhibition of MMPs, especially the two gelatinases MMP-2 and MMP-9 responsible for degradation of collagen IV found in basement membranes, is considered as a potential modality in cancer treatment. 8 ACEi's containing a thiol radical (such as captopril and CL242817) have been shown to control MMP activity. However, although these properties may be pharmacologically relevant, the blockade of Ang II synthesis or action itself seems to play an essential role in the cytostatic activity, as shown with both ACEis and ARBs. 6 Figure 1 depicts the possible interactions between components of the RAS and factors related to carcinogenesis. Table 1 lists a number of experimental studies in vitro and in animals, which show the effect of various components of the RAS on the growth and proliferation of malignancies, as well as the protective effects of inhibition of such components.
Breast cancer
Tahmasebi et al. 10 have proposed the hypothesis that components of the RAS are present in the breast, and are disrupted in invasive cancer. mRNA coding for angiotensinogen, prorenin, ACE, and both AT 1 and AT 2 receptors was shown in normal and diseased breast tissues. Prorenin was identified in epithelial cells in both normal and diseased tissue, but in invasive carcinoma, its distribution was mostly confined to fibroblasts or could not be detected at all, and ACE was shown in epithelial cells in both normal and malignant tissue.
It was shown by De Paepe et al. 11, 12 that the expression of AT 1 receptors on the cell membrane disappears in invasive breast cancer cells, suggesting a regulatory pathway that is no longer needed in invasive carcinoma. On the contrary, AT 2 receptor levels are low in normal ducts but increase in breast hyperplasia and invasive breast carcinoma, concomitantly with increase in inducible nitric oxide synthase (iNOS), an enzyme that has been associated with cancer. Their conclusion was that the specific AT 1 receptor expression upregulation might well be an important step in the pathogenesis of hyperplasia of the breast, which is regarded as a precursor lesion for breast cancer.
Targeting tumour angiogenesis by using candesartan was discovered by Herr et al. 13 in receptornegative breast cancer cells. This was described as the first evidence that breast tumour angiogenesis can be inhibited by using AT 1 R antagonists, a finding that may lead to a new therapeutical strategy in treatment of breast cancer.
Small et al. 14 evaluated the effect of the ACEi captopril on oestrogen and progesterone receptor concentrations and on proliferation in two lines of human mammary ductal carcinoma cells in culture. The incorporation of [ 3 H]uridine (RNA synthesis) and [ 14 C]alanine (protein synthesis) was inhibited by captopril, suggesting a general antimetabolic effect of the drug in the ductal carcinoma cells. The nonthiol ACE inhibitor lisinopril, however, had no effect on any of these end points. Growth of mammary gland tumours induced by N-methyl-Nnitrosourea in Wistar rats was studied by Chochieva et al. 15 Captopril administered at a dose of 50 mg kg -1 twice weekly significantly decreased the tumour growth rate.
Uterine and ovarian cancer
In vitro experiments by Isobe et al. 16 confirmed the expression of AT 1 and AT 2 receptor mRNA in leiomyoma cells and showed that Ang II induced ELT-3 leiomyoma cell proliferation. The ARB telmisartan effectively repressed Ang II-induced and estradiol-induced cell proliferation, and the experiments suggested that only the AT 1 receptor plays a role in Ang II-induced ELT-3 cell proliferation. Ang II significantly enhanced the invasive potential and VEGF secretion in AT 1 -positive SKOV-3 ovarian cancer cells, both of which were completely inhibited by the ARB candesartan. Administration of candesartan into SKOV-3-transplanted athymic mice resulted in the reduction of peritoneal dissemination, decreased ascitic VEGF concentration and suppression of tumour angiogenesis. 17 Prostatic cancer Ishiguro et al. 18 reported that Ang II activated the proliferation of prostate cancer cells and the ARB telmisartan inhibited the proliferation of prostate cancer in vitro and in vivo. The results of this study suggested that cell proliferation and signal transduction were inhibited by telmisartan treatment, which would imply that an ARB could have an effect similar to that of an anti-androgenic agent in prostate cancer cells. The capacity of ARBs for molecular targeting affecting both mitogenesis and angiogenesis in prostate cancer was also shown by Uemura et al. 19, 20 Liver cancer Experimental studies have shown that the ACE inhibitors captopril and perindopril decrease preneoplastic lesions and hepatic carcinoma cell growth. 21, 22 In mice with BNL-hepatic carcinoma, treatment with perindopril decreased tumour growth, angiogenesis and VEGF, unlike treatment with the ARBs losartan or candesartan, suggesting that the antineoplastic effect might be independent of the formation or action of Ang II. [23] [24] [25] However, Ang II induces the expression of the potent angiogenic factor VEGF, which would be expected to enhance tumour growth and migration. Additional studies have suggested that several ACEis are potent inhibitors of experimental tumour development and angiogenesis at equivalent doses, as they can suppress VEGF expression in tumours. 26 Noguchi et al. 27 suggested that the combination treatment of hepatocellular carcinoma with perindopril and interferon-b at clinically comparable low doses could inhibit tumour development and angiogenesis and suppress VEGF. As both agents are widely used in clinical practice, this combination regimen may represent a potential new therapeutic strategy in the future. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by the combination of 5-fluorouracil and an ACEi was reported by Yanase et al. 28 Yoshiji et al. 29, 30 reported that treatment with vitamin K and an ACEi exerted potent anti-angiogenic activities and ameliorated hepatic dysplastic nodules in a patient with liver cirrhosis. After 1 year of treatment, not only did the serum levels of afetoprotein (AFP) and lectin-reactive demarcation (AFP-L3) return to the normal ranges, but also the dysplastic nodule disappeared. These authors studied the effects of combination treatment with vitamin K in hepatocarcinogenesis induced by diethyl-nitrosamine and orthotopic hepatocellular carcinoma growth in rats, and they too concluded that this could become an effective new therapeutic strategy in the future.
Renal cell carcinoma
The effect of captopril on tumour growth was examined in a xenograft model of human renal cell carcinoma. Inoculation of these cells to immunodeficient mice resulted in large tumours. In mice treated with captopril, there was a significant doserelated reduction in tumour development. 31 Pulmonary metastases of renal cell carcinoma showed prominent AT 1 receptor expression in both mice and humans, and candesartan treatment dramatically prevented lung metastatic nodules in mice, along with the inhibition of neovascularization and VGEF expression, compared with control mice. 32 
Pancreatic adenocarcinoma
Experimental studies using cultured hamster pancreatic cancer cells have shown that captopril and the ACEi CGS 13945 decreased cell proliferation, as well as the cell proliferation antigen (PCNA), a DNA polymerase cofactor that is used as a marker for synthesis phase. Pancreatic cells lack renin and ACE activity, and yet, both ACEis produced a dosedependent reduction in tumour cell proliferation within 24 h. This suggests that the antimitotic action of captopril and CGS 13945 may be independent of renin-angiotensin regulation and the growth inhibition may occur through downregulation of growthrelated gene expression. 33 Hypovascularity is an outstanding characteristic of pancreatic ductal cancer as tumour vessels are seldom seen on angiography. Ohta et al. 34 examined whether a local Ang II-generating system exists in pancreatic ductal cancer tissue. They found that tissue Ang II levels in pancreatic ductal cancer were significantly higher than those of normal pancreas, colon cancers or hepatocellular carcinomas. However, there was no significant difference in tissue ACE activity between them, suggesting that Ang II formed locally by an ACE-independent system may act on the pre-existing pancreatic arteries around the tumour, leading to formation of hypovascular or avascular regions.
The likely mechanism is inhibition of VEGF, whose high expression levels have been correlated with poor prognosis and early postoperative recurrence. 35 Indeed, ACE and AT 1 receptor mRNA and protein levels were significantly upregulated in 19 of the 25 neoplastic tissues examined (approximately 75%), when compared with matching controls. VEGF expression was significantly higher in tissues that expressed high levels of AT 1 receptor and ACE, compared with low levels or negative cases. ACE protein colocalized with AT 1 receptor and VEGF in the malignant ducts and in the stromal cells. Addition of Ang II significantly enhanced VEGF mRNA production and protein secretion, an effect that was prevented when cells were preincubated with captopril or losartan. 35 Colon cancer Ang II receptors were detected on cells of three colorectal carcinoma cell lines. The binding assays with 125 I-labelled Ang II and ligands specific for AT 1 and AT 2 receptors showed that Ang II receptors on colorectal cancer cells are mostly of the AT 2 type. 36 In AT 2 receptor-deficient mice, azoxymethane-induced colon tumour prevalence was decreased to 11% compared with 100% in control animals, whose size and number of tumours were also significantly higher. This suggested that AT 2 receptor activation could be crucial during tumour genesis and growth, representing a potential mechanism of chemoprevention for human colorectal cancer. 37 
Lung carcinoma
The anticancer activity of captopril in athymic mice injected with highly tumourigenic LNM35 human lung cells as xenografts was investigated by Attoub et al., 38 who showed that daily i.p. administration of captopril (2.8 mg per mouse) for 3 weeks resulted in a remarkable reduction of tumour growth (58%) and lymph node metastasis (50%). Immunohistochemical analysis showed that captopril treatment significantly reduced the number of proliferating cells but did not inhibit angiogenesis; rather it inhibited the viability of LNM35 cells by inducing apoptosis.
Administration of thiorphan alone at a dose of 25 mg per mouse or in combination with bestatin or captopril decreased the number of spontaneous metastases in lungs of Lewis lung carcinoma-bearing mice. Neither the injections of bestatin and captopril nor bestatin in combination with captopril influenced the number of lung tumour colonies. 39 According to Prontera et al., 40 the effect of the synthetic MMP-2 inhibitor batimastat and captopril resulted in 51 and 80% inhibition, respectively, of tumour growth and metastases. Captopril pretreatment augmented the antitumour action of cyclophosphamide, expressed in terms of the survival time and the number of cured mice. 41 Melanoma Subcutaneous B16-F1 melanoma-induced angiogenesis was prominent in wild-type (WT) mice, but was reduced in AT 1a receptor-deficient (AT 1a À/À) mice, indicating that host AT 1 receptor plays an important role in angiogenesis and growth of tumour cells engrafted in mice. Additionally, administration of the ARB TCV-116 significantly decreased melanoma tumour volume in WT mice. 42 Angiostatin, a proteolytic fragment of plasminogen consisting of the first three or four kringle domains, was readily detectable in mice receiving both tissue plasminogen activator (tPA) and captopril, but not in mice receiving either of the agents. The anti-tumour activity of the tPA/captopril treatment was tested in a human melanoma xenograft model. Administration of tPA alone had only a marginal effect on tumour growth. Captopril alone reduced tumour growth by about 60%, whereas treatment with both captopril and tPA resulted in 83% inhibition of tumour growth. 43 
Brain tumours
Renin and angiotensinogen mRNAs and proteins were found by in situ hybridization and immunohistochemistry in human glioblastoma cells, and angiotensinogen was present in glioblastoma cystic fluids. Inhibition of ACE, mainly expressed in tumour blood vessels, and inhibition of renin in glioblastoma cells, could be a potential approach to control cell proliferation and glioblastoma progression in combination therapy. 44 Normal and tumour astrocytes express all angiotensin receptor subtypes. This supports the idea that Ang (1-7) and its receptor signalling system may play an important role in shaping the astrocyte population during development. Moreover, the untimely expression of the Ang (1-7) receptor may represent an important aetiological component in the development of brain astrocytomas. Expression of both AT 1a and AT 2 receptor mRNA has also been detected in astrocytoma cell lines. 45 Captopril inhibits the invasiveness of culture media of T98G glioma cells because of its MMP inhibitory activity, which was reversed by addition of zinc to the media. However, at the effective concentration of captopril for the prevention of tumour cell invasion it did not inhibit the motility, adhesion to Matrigel or proliferation of T98G. 46 The ARB losartan also inhibits the production of several growth factors, including VEGF, and reduces rat C6 glioma cell growth in vitro and in vivo.
47
Human SH-SY5Y neuroblastoma cells were treated with captopril, enalapril or enalaprilat, or saralasin. In all cases, statistically significant reductions in cell growth were seen over 5 days of culture. In additional experiments, captopril and enalaprilat significantly decreased thymidine incorporation into DNA in these cells. 48 Eye When used systemically on rats, captopril inhibited corneal neovascularization and showed the antitumour activity expected of an inhibitor of angiogenesis. 21 Sarcoma and fibrosarcoma Treatment with captopril inhibited fibrosarcoma growth in a rat model by slowing of growth rate of experimental fibrosarcoma, even though these cells were resistant to captopril in vitro. 21 Both the ARB TCV-116 and the ACEi lisinopril inhibited tumour growth, tumour-associated angiogenesis and metastasis in a murine model of sarcoma. The growth of sarcoma 180 (S-180) cells and of fibrosarcoma cells was strongly inhibited by administration of TCV-116 in the diet at a dose of approximately 100 mg kg -1 day -1 , along with a marked reduction in tumourassociated angiogenesis. 49, 50 Basal cell carcinoma Captopril also reduces chronic benign and malignant skin reactions in the radiation treatment field. The beneficial effect of captopril on the severity of radiation-induced epilation and moist desquamation and the incidence of skin tumours was determined for up to 52 weeks in male rats. 51 Takeda and Kondo 52 studied immunohistochemically the expression of Ang II receptors in the human skin. Their experiments showed that high, intermediate and low levels of AT 1 receptor were observed in 37 (74.0%), 7 (14.0%) and 2 (4.0%) of 50 cases of squamous cell carcinoma of the skin, respectively, and a negative pattern was observed in 17 (77.3%) of 22 cases of keratoacanthoma.
Immunohistochemical study of the expression of AT 1 and AT 2 receptors in human anagen hair follicles and in 16 cases of basal cell carcinoma showed positive staining with AT 1 in the tumour cells of basal cell carcinoma with follicular differentiation, suggesting that this receptor may have a role in follicular keratinization. 53 
Clinical observations
Subsequent to the original publication of Lever et al.
1, reporting lower incidence of cancers in patients treated with ACEis, a number of epidemiological studies failed to reproduce these results. One was a case-control study-a part of the Boston Collaborative Drug Surveillance Program-that included 3706 postmenopausal women with breast carcinoma who had earlier exposure to antihypertensive treatment, including ACE inhibitors. Comparison with a matched control group of 14 155 women did not support the hypothesis that use of ACE inhibitors affects the risk of malignancy. 54 Stahl et al. Likewise, in the population-based Prescription Database of North Jutland County and the Danish Cancer Registry, cancer incidence among 17 897 individuals prescribed ACEis did not confirm a protective effect of ACEi on the development of cancer. 56 In the Swedish trial STOP-Hypertension-2, comprising 6614 hypertensives, there were 625 new cases of cancer in 590 patients. Frequency did not differ significantly between patients randomly assigned to conventional drugs, calcium antagonists, or ACEis. 57 Another population-based case-control study conducted in western Washington State included 975 women aged 65-79 years who were diagnosed with invasive breast carcinoma during 1997-1999. It found that there was no difference in the risk of breast carcinoma related to use of antihypertensive medications. 58 Of course, the lack of association between use of ACE inhibitors and the reduction in cancer risk in most of the retrospective studies does not prove that Ang II does not participate in neoplasm development, nor that the inhibition of the RAS has no antineoplastic activity. Indeed, the Rotterdam Study, a population-based, prospective cohort study that recorded cases of 730 cancers over a 9.6-year followup period, investigated the effect of RAS inhibition, ACE I/D genotypes, and their interaction on cancer risk and progression. RAS-inhibiting drugs seemed to protect against cancer in individuals with the DD genotype, which was associated with high levels of ACE. 59 Breast cancer An epidemiological study conducted in Chinese women in Singapore observed lower breast-cancer incidence in users of ACE inhibitors relative to nonusers with comparable cardiovascular conditions, 60, 61 consistent with experimental data implicating ACE and Ang II in breast cancer.
As earlier studies have shown that the ACE gene I/D polymorphism accounts for the variability of ACE plasma concentrations, it was hypothesized that an interaction between the use of ACEis and the ACE I/D polymorphism may be linked to risk of breast cancer. González-Zuloeta Ladd et al. 62 found that in Caucasian postmenopausal women the cancer-free survival was significantly reduced in carriers of the DD compared with the II alleles and concluded that the ACE I/D polymorphism plays an important role in this respect. Another study reached the same conclusion, that is, that the DD genotype may accompany poor prognostic factors and influence the tumour course. 63 Ovarian and uterine cancer Kikkawa et al. 64 reported that Ang II, acting through its AT 1 receptor, induces the secretion of VEGF, which results in increased invasiveness of carcinoma cells. The AT 1 receptor is expressed in invasive ovarian adenocarcinomas and borderline malignant tumours, but in only 2 of 14 (14%) benign cystadenomas. In invasive carcinomas, VEGF expression intensity and intratumour microvessel density were significantly higher in cases strongly positive for the AT 1 receptor compared with cases weakly positive or negative for this receptor.
When the ACE gene polymorphism was analysed in normotensives, it was found that presence of the I allele (genotypes ID and II) is significantly associated with an earlier age (56.0±10.1 versus 65.8 ± 9.9) of onset of endometrial carcinoma. These findings suggest that ACE polymorphism may be associated with the development of endometrial carcinoma and with the onset of this tumour in younger women. 65 Endometriosis and leiomyoma show features similar to malignancy, requiring neovascularization for proliferation and growth, so that altered vascular-related genes might be related to their development. Hsieh et al. 66 reported that ACE genotypes and alleles are strongly related to the occurrence of endometriosis and moderately related to the susceptibility for leiomyoma.
Prostate cancer
Although no clear association was apparent between the use of antihypertensive drugs and prostate cancer, specific focus on users of captopril showed a lower risk of subsequent prostate cancer. 67 Data published by Uemura et al. 19 suggest that prostatic RAS is overexpressed in hormone refractory prostate cancer tissue, and expression of its components is influenced by several kinds of hormonal stimulation. It has been reported that ACE is synthesized by the prostate and that the AT 1 receptor subtype is the predominant prostatic Ang II receptor. The highest levels of circulating and tissue ACE activity are found in carriers of the DD genotype. The data support the hypothesis that genetic factors related to ACE may influence the behaviour of human prostate cancer and that ARBs may have a role in its treatment. Consistent with this, a 50% reduced risk of advanced versus localized prostate cancer was also reported in Portuguese men with the II genotype. 68 Additional evidence by Yigit et al. 69 supports the notion that the risk of prostate cancer development, the prostate-specific antigen level and tumour metastasis may be associated with genetic variation in the ACE I/D genotypes, which may be used as an important biomarker for further studies. Röcken et al. 76 reported that ACE is expressed locally in gastric cancer and that the ACE gene polymorphism influences metastatic behaviour. Twenty-four of 113 (21%) gastric cancer patients had the II, 57 (51%) the ID, and 32 (28%) the DD genotype. The distribution of the ACE genotypes did not differ significantly from the control group of 189 patients without gastric cancer. However, patients with the II genotype had significantly smaller number of lymph node metastases and a significantly lower UICC (International Contra Cancrum) tumour stage than patients with the DD genotype. Sugimoto et al. 5 also proposed that the ACE gene, as well as the chymase gene polymorphisms, are associated with differences in risk for gastric cancer.
Gastrointestinal cancers
Carl-McGrath et al. 77 reported that increased gene expression of various components of the RAS in gastric cancer may promote tumour cell invasion of lymph nodes. They found significant upregulation of the ACE, AT 1 and AT 2 receptors in gastric tumour and lymphatic metastases. Neo et al. 78 investigated the effects of captopril and irbesartan in hepatic metastases of colorectal cancer. Both captopril and irbesartan markedly decreased tumour growth when compared with control. However, there was no significant difference in survival or tumour necrosis for either of the drugs.
Skin cancers
Christian et al. 79 evaluated data on 1051 participants in the randomized Department of Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial, all of whom were at increased risk of basal cell carcinoma or squamous cell carcinoma. Participants were followed from enrolment until first detection of cancer for an average of 4 1 2 years. The results indicated that among a high-risk group of veterans, users of ACEis or ARBs had a lower incidence of keratinocyte cancers than nonusers. The more pronounced reduction among those who initiated use during the study may indicate an immediate effect.
According to Stanojkovic et al., 80 captopril at concentrations 41 mmol led to a statistically significant inhibition of proliferation of melanoma cells.
Conclusions
Treatment with ACEis and ARBs may decrease the production of growth factors in neoplasms with positive receptors, representing an adjuvant therapy with synergistic effects to chemotherapy. However, the anticancer effect of Ang II inhibition is not yet clear. Whereas in some tumours it seems to be mediated by AT 1 receptor blockade, it is possible that Ang II inhibition produced AT 1 /AT 2 stimulation disequilibrium that favored AT 2 stimulation and would lead cells to apoptosis. 4 The results from the epidemiological studies are conflicting, and even taking the different methodology and endpoints into consideration, it is not possible to make definite inferences from these. 8 Investigation is needed beyond the observation period of most of these studies, 56 and additional experimental studies are needed also to study the mechanisms by which agents blocking the RAS may obtain their inhibitory effect on tumour growth and metastasis. 31 Angiotensin-converting enzyme inhibitors should be investigated in properly designed prospective clinical trials of patients with cancer. This approach faces the same problems as in trials with MMP inhibitors and other biological modifiers: identification of patients with minimal tumour burden, useful surrogate end points along with decisions about what doses to use. 8 Furthermore, it is important to understand the different role of factors affected by ACEi (angiotensin and/or bradykinin) and their importance in angiogenesis in a given pathology before considering their clinical use for cancer therapy. 81 
